The treatment reshapes the anatomy of the prostatic urethra, gently creating a wider opening for urine to flow freely, without burning or cutting out tissue, and without leaving behind a permanent implant.
The iTind procedure is straightforward, is an outpatient procedure done in clinic, and has none of the side effects associated with prescription medication. Developed to meet the needs of active patients, the passive 5 to 7-day treatment period helps minimize downtime and does not compromise sexual function. That means you are back to yourself, and back to your daily routine, in no time at all.
Find your BPH symptom score.
Consult with our world-class medical experts within days of your call.
A cystoscope is a miniature camera which will be inserted into your urethra to place the iTind device in your prostatic urethra. Once in place you should be able to urinate freely, so there is no need for a catheter and you will be released to go home.
During the next 5 to 7 days you may resume most normal activities, depending on how comfortable you feel. The most common side effect reported while the iTind is in place is pressure around the area of the perineum and increased urgency and frequency to urinate. Some patients also experience some light blood in their urine and slight burning when urinating.
After 5 to 7 days, your doctor will completely remove the iTind device using a flexible silicone catheter. Once this is done, you may return to your normal life.
The insertion of the iTind device into the prostatic urethra generally takes a few short hours. Following the initial insertion, it takes 5 to 7 days for the iTind device to widen the prostatic urethra, during which patients may resume their daily activities.
After insertion of the iTind device, you may be kept for a few hours for observation. Upon returning home you may resume most normal activities depending on your personal level of comfort.
Effective BPH symptom relief with minimally invasive and low risk treatments.
The most common side effects experienced are the feeling of pressure in the area of the perineum, an increased frequency and urgency to urinate, light blood in urine, and slight burning upon urination.
In clinical studies there have been no indications of long-term adverse side effects. Since the iTind device is completely removed after it has done its job to widen the opening at the prostatic urethra, there is no risk of implant migration, encrustation, or tissue overgrowth that could complicate removal. Moreover, there are no obstacles in maintaining a regular prostate screening program, including physical exams or any type of imaging, such as MRI, if needed.
In terms of pain, most patients experience only mild to moderate discomfort while the iTind is in place, however patient experience is variable.
Clinical data demonstrates three years durability of the first generation TIND and efficacy at 24 months of the second-generation iTind. Both studies demonstrated preservation of sexual function and urinary continence and a very high safety profile. You can view resources here.
AR
HY
ZH-CN
EN
DE
EL
IT
FA
PT
ES
TR
JP
